Job opportunities

CEO

Company introduction

Catapult Therapeutics is a privately held Dutch biotech company developing CAP-100 – an innovative first-in-class humanized anti-CCR7 antibody.

Catapult Therapeutics was established in 2015 as a joint venture between Spanish and Dutch partners. Catapult is founded on the discoveries of Dr Cecilia Munoz and her group at Hospital La Princesa in Madrid. They identified and validated CCR7 as a therapeutic target for leukemias and lymphomas. Technology of Dutch biotech company Pepscan made it possible to generate antibodies against human CCR7.

The chemokine receptor CCR7 is over-expressed in many cancers, and high CCR7 expression is associated with poor prognosis and short survival in hematological and solid malignancies. Preclinical studies have shown that the anti-CCR7 antibody can prolong survival and inhibit cancer cell migration in multiple animal models of B-cell and T-cell lymphomas.

CAP-100 has a uniquely differentiated mechanism of action, which is complementary to current standard of care treatments for hematological malignancies. Thus, CAP-100 is a potential monotherapy and can be used in combination with current standard treatments.

Catapult  is currently finalizing the preclinical development of CAP-100, which will be  will be IND ready in  Q3 2020.  The preparations for the start of the first study in patients are ongoing.

 The opportunity

Catapult Therapeutics is currently entering the clinical trial phase 1. To realize our ambition, we are looking for a hands-on CEO with proven track record in international business development and partnering as well as operational experience in running clinical trials.

 Proficiencies

The ideal candidate with life science background is entrepreneurial, is driven by growing the business to the optimum level for treatment of humans and is thrilled by being in the frontline of breakthrough developments in cancer therapies. The candidate has a good understanding of stakeholder management, he/ she is accountable as project manager, has an overview of the pharmaceutical industry, and has a sound understanding of the pharmaceutical development process and more specifically he/ she has clinical trial experience. It’s a great advantage if the candidate has led the successful early clinical development and partnering of a new product.

Your responsibilities

• Operational leadership of the Phase I/II clinical development of CAP-100
• Ensure Catapult Therapeutics’s capabilities are known and recognized by potential business partners
• Bring business opportunities to fruition and develop long-term relationships
• Remain engaged in ongoing projects to help ensure that (customer) expectations are fully met at all times
• Gather and communicate relevant market information to the board; stakeholder management

Your education/experience

• Higher level of education (B.Sc./M.Sc.) in a relevant discipline such as medicine, medical biology, pharmaceutical sciences   or (bio)chemistry
• Operational experience in clinical development
• Experience in business development and stakeholder management
• Successful track record in selling (including negotiation and deal closure skills)
• Demonstrated success in building relationships on trust, engagement and long-term commitment

Your profile

• Entrepreneurial
• Excellent interpersonal skills
• Excellent oral and written communication skills (English)
• Commercial drive
• Willing to travel abroad to visit (potential) partners (mainly US/EU)
• Project management skills

What we offer

The position offers an opportunity to work within a small team, with great autonomy and entrepreneurial, science-loving colleagues, all of whom are committed to improving the lives of patients.

Catapult Therapeutics’s offers an informal ambitious working environment. We offer a market conform salary and a good pension plan. The right candidate will be welcomed enthusiastically.